Takeda Pharmaceutical Showcases Strong Phase III Psoriasis Data for Zasocitinib, Eyes 2027 Launch [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
Takeda Pharmaceutical (NYSE:TAK) highlighted late-breaking Phase III data for investigational TYK2 inhibitor zasocitinib in moderate-to-severe plaque psoriasis and outlined its commercial plans during a company presentation tied to the American Academy of Dermatology (AAD) annual meeting. Company context and upcoming launches CEO-Elect Julie Kim said Takeda is entering what she described as “a new chapter of growth,” citing three pivotal readouts in the prior year for oveporexton, zasocitinib, and rusfertide. Kim said the company is preparing for three major launches over the next 15 months. ? Quiet BNY and Northern Trust Reward Patient Investors Time to buy these 3 healthcare companies that raised revenue guidance? Kim reviewed two other programs briefly: Oveporexton , an orexin receptor 2 agonist for narcolepsy type 1 (NT1), has an FDA-accepted New Drug Application (NDA) with priority review and an August PDUFA date. Kim said Takeda is positioned for a launch in the sec
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- AI in Pharmacovigilance Course: Comprehensive Introduction to the Transformative Impact of Artificial Intelligence on Drug Safety and Monitoring (ONLINE EVENT: May 18, 2026) [Yahoo! Finance]Yahoo! Finance
- Takeda Pharmaceutical (TAK) was upgraded by Sanford C. Bernstein from "market perform" to "outperform".MarketBeat
- Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment [Yahoo! Finance]Yahoo! Finance
- Major biopharmaceutical company to lay off nearly 250 workers in MA [Yahoo! Finance]Yahoo! Finance
- DIA's LIFT Series Brings Startup Pitch Competitions, Innovation Programming to Global Annual Meeting [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 4/6/26 - Form 3
- 4/6/26 - Form 3
- 4/6/26 - Form 3
- TAK's page on the SEC website